Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Dexamethasone 21-phosphate disodium salt

$68

  • Brand : BIOFRON

  • Catalogue Number : AV-B81210

  • Specification : 98%

  • CAS number : 2392-39-4

  • Formula : C22H30FO8P

  • Molecular Weight : 516.4

  • PUBCHEM ID : 16961

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-B81210

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

516.4

Appearance

Botanical Source

Structure Type

Category

Standards;Natural Pytochemical;API

SMILES

CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COP(=O)([O-])[O-])O)C)O)F)C.[Na+].[Na+]

Synonyms

Turbinaire/Dexamethasone 21-Phosphate Disodium Salt Hydrate/Oradexon/Hexadrol/Solu-Decadron/Disodium 2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl phosphate/Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, sodium salt, (11β,16α)- (1:2)/Dalalone/Wymesone/DEXAMETHASONE DISODIUM PHOSPHATE/Dexamethasone Sodium Phosphate/Disodium (11β,16α)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl phosphate/Dexamethasone 21-phosphate disodium salt/Dinatrium-2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluor-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxoethylphosphat phosphate de 2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyle de disodium/DEXAMETHASONE 21-(DISODIUM PHOSPHATE)/Dezone/9-Fluoro-11b,17,21-trihydroxy-16a-methylpregna-1,4-diene-3,20-dione 21-(Dihydrogen Phosphate) Disodium Salt/Soldesam/Dexamethasone phosphate disodium

IUPAC Name

disodium;[2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate

Applications

Dexamethasone phosphate disodium is a glucocorticoid receptor agonist.

Density

1.32g/cm3

Solubility

Flash Point

358.7ºC

Boiling Point

669.6ºC at 760 mmHg

Melting Point

233-235 °C

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

3822000000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:2392-39-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

29610175

Abstract

Two infants with disseminated adenoviral infections are described. Both these infants had a similar clinical course and were also diagnosed with secondary hemophagocytic lymphohistiocytosis (HLH). Previous reports of immunocompromised adults with adenovirus-associated HLH are in the literature; however, this is the first report that we are aware of with this pathology occurring in infants. These cases are used to demonstrate the importance of thinking about HLH in patients who are diagnosed with adenovirus and exhibit prolonged fevers that are unresponsive to antimicrobial agents with hepatosplenomegaly and cytopenias.

Copyright ? 2018 by the American Academy of Pediatrics.

Title

Neonatal Adenovirus Infection Complicated by Hemophagocytic Lymphohistiocytosis Syndrome

Author

Nina Censoplano 1, Stephen Gorga 2, Kate Waldeck 2, Terri Stillwell 3, Raja Rabah-Hammad 4, Heidi Flori 2

Publish date

Apr 2018

PMID

30497073

Abstract

Dexamethasone phosphate is widely used for intratympanic therapy in humans. We assessed the pharmacokinetics of dexamethasone entry into perilymph when administered as a dexamethasone phosphate solution or as a micronized dexamethasone suspension, with and without inclusion of poloxamer gel in the medium. After a 1-h application to guinea pigs, 10 independent samples of perilymph were collected from the lateral semicircular canal of each animal, allowing entry at the round window and stapes to be independently assessed. Both forms of dexamethasone entered the perilymph predominantly at the round window (73%), with a lower proportion entering at the stapes (22%). When normalized by applied concentration, dexamethasone phosphate was found to enter perilymph far more slowly than dexamethasone, in accordance with its calculated lipid solubility and polar surface area properties. Dexamethasone phosphate therefore has a problematic combination of kinetic properties when used for local therapy of the ear. It is relatively impermeable and enters perilymph only slowly from the middle ear. It is then metabolized in the ear to dexamethasone, which is more permeable through tissue boundaries and is rapidly lost from perilymph. Understanding the influence of molecular properties on the distribution of drugs in perilymph provides a new level of understanding which may help optimize drug therapies of the ear.

KEYWORDS

Dexamethasone; Dexamethasone phosphate; Elimination; Intratympanic therapy; Lipid solubility; Perilymph; Permeability; Polar surface area; Round window; Stapes.

Title

Dexamethasone and Dexamethasone Phosphate Entry Into Perilymph Compared for Middle Ear Applications in Guinea Pigs

Author

Alec N Salt 1, Jared J Hartsock 2, Fabrice Piu 3, Jennifer Hou 3

Publish date

2018

PMID

27755433

Abstract

Introduction: The purpose of this prospective randomized controlled clinical trial was to evaluate the effect of oral administration of bromelain on discomfort after mandibular third molar surgery.

Materials and methods: Eighty-four consecutive patients requiring surgical removal of a single mandibular impacted third molar under local anesthesia were randomly assigned to receiving no drug (control group, Group A), postoperative 40 mg bromelain every 6 hours for 6 days (Group B), preoperative 4 mg dexamethasone sodium phosphate as a submucosal injection (Group C), and preoperative 4 mg dexamethasone sodium phosphate as a submucosal injection plus postoperative 40 mg bromelain every 6 hours for 6 days (Group D). Standardized surgical and analgesic protocols were adopted. Maximum interincisal distance and facial contours were measured at baseline and on postoperative days 2 and 7. Pain was measured objectively by counting the number of analgesic tablets required. Patient perception of the severity of symptoms was assessed with a follow-up questionnaire (PoSSe scale).

Results: On postoperative day 2, there was a statistically significant reduction in facial edema in both Groups C and D compared with the control group, but no statistically significant differences were observed between Group B and the control group. At evaluation on postoperative day 7, Group D showed a statistically significant reduction in postoperative swelling compared with the control group. The combined use of bromelain and dexamethasone (Group D) induced a statistically significant reduction in the total number of analgesic tablets taken after surgery compared with the control group. The treatment groups had a limited, nonsignificant effect on trismus when compared with the control group.

Conclusions: Bromelain used singly showed moderate anti-inflammatory efficacy, reducing postoperative swelling, albeit not to any significant extent compared with no drug administration. The combined use of bromelain and dexamethasone sodium phosphate yielded the best results in terms of control of postoperative discomfort.

Title

Effect of Oral Administration of Bromelain on Postoperative Discomfort After Third Molar Surgery

Author

Paolo Ghensi 1, Alessandro Cucchi, Luca Creminelli, Cristiano Tomasi, Barbara Zavan, Carlo Maiorana

Publish date

Mar 2017